TY  - GEN
AU  - Wong,A L
AU  - Soo,R A
AU  - Tan,D S
AU  - Lee,S C
AU  - Lim,J S
AU  - Marban,P C
AU  - Kong,L R
AU  - Lee,Y J
AU  - Wang,L Z
AU  - Thuya,W L
AU  - Soong,R
AU  - Yee,M Q
AU  - Chin,T M
AU  - Cordero,M T
AU  - Asuncion,B R
AU  - Pang,B
AU  - Pervaiz,S
AU  - Hirpara,J L
AU  - Sinha,A
AU  - Xu,W W
AU  - Yuasa,M
AU  - Tsunoda,T
AU  - Motoyama,M
AU  - Yamauchi,T
AU  - Goh,B C
TI  - Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
SN  - 1569-8041
PY  - 2016///0519
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Asia
KW  - Biomarkers, Tumor
KW  - antagonists & inhibitors
KW  - Biotransformation
KW  - Carcinoma, Non-Small-Cell Lung
KW  - blood
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - ErbB Receptors
KW  - genetics
KW  - Female
KW  - Half-Life
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Metabolic Clearance Rate
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Mutation
KW  - Phosphorylation
KW  - STAT3 Transcription Factor
KW  - Signal Transduction
KW  - drug effects
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdv026
ER  -